Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

CONCLUSION: The CPP of relatlimab alone or in combination with nivolumab supports the approved dosing in advanced melanoma and the continued evaluation of nivolumab and relatlimab across other solid tumors.PMID:38295151 | DOI:10.1158/1078-0432.CCR-23-2396

Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Yue Zhao Zheyi Hu Sai Praneeth Bathena Sarah Keidel Karen Miller-Moslin Paul Statkevich Akintunde Bello Amit Roy Satyendra Suryawanshi Source Type: research